In this section
The publication feed below is often incomplete and out of date; for an up to date summary of our publications please see Google Scholar or Pub Med
@article{Goya:2021:10.1016/j.tips.2021.07.004,
author = {Goya, Grocin A and Kallemeijn, W and Tate, E},
doi = {10.1016/j.tips.2021.07.004},
journal = {Trends in Pharmacological Sciences},
pages = {870--882},
title = {Targeting methionine aminopeptidase 2 in cancer, obesity and autoimmunity},
url = {http://dx.doi.org/10.1016/j.tips.2021.07.004},
volume = {42},
year = {2021}
}
TY - JOUR
AB - For over three decades, methionine aminopeptidase 2 (MetAP2) has been a tentative drug target for the treatment of cancer, obesity, and autoimmune diseases. Currently, no MetAP2 inhibitors (MetAP2i) have reached the clinic yet, despite considerable investment by major pharmaceutical companies. Here, we summarize the key series of MetAP2i developed to date and discuss their clinical development, progress, and issues. We coalesce the currently disparate knowledge regarding MetAP2i mechanism of action and discuss discrepancies across varied studies. Finally, we highlight the current knowledge gaps that need to be addressed to enable successful development of MetAP2 inhibitors in clinical settings.
AU - Goya,Grocin A
AU - Kallemeijn,W
AU - Tate,E
DO - 10.1016/j.tips.2021.07.004
EP - 882
PY - 2021///
SN - 0165-6147
SP - 870
TI - Targeting methionine aminopeptidase 2 in cancer, obesity and autoimmunity
T2 - Trends in Pharmacological Sciences
UR - http://dx.doi.org/10.1016/j.tips.2021.07.004
UR - http://hdl.handle.net/10044/1/102175
VL - 42
ER -
Prof. Ed Tate
GSK Chair in Chemical Biology
Department of Chemistry
Molecular Sciences Research Hub, White City Campus,
82 Wood Lane, London, W12 0BZ
e.tate@imperial.ac.uk
Tel: +44 (0)20 759 + ext 43752 or 45821